Literature DB >> 23139022

Identification of small molecules that interfere with H1N1 influenza A viral replication.

Angel Bottini1, Surya K De, Bas J G Baaten, Bainan Wu, Elisa Barile, Stephen Soonthornvacharin, John L Stebbins, Linda M Bradley, Sumit K Chanda, Maurizio Pellecchia.   

Abstract

Successful replication of the influenza A virus requires both viral proteins and host cellular factors. In this study we used a cellular assay to screen for small molecules capable of interfering with any of such necessary viral or cellular components. We used an established reporter assay to assess pan class="Species">influenza viral replication by monitoring the activity of co-expressed luciferase. We screened a diverse chemical compound library, resulting in the identification of compound 7, which inhibits a novel yet elusive target. Quantitative real-time PCR studies confirmed the dose-dependent inhibitory activity of compound 7 in a viral replication assay. Furthermore, we showed that compound 7 is effective in rescuing high-dose influenza infection in an in vivo mouse model. As oseltamivir-resistant influenza strains emerge, compound 7 could be further investigated as a new and potentially suitable scaffold for the development of anti-influenza agents that act on novel targets.
Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23139022      PMCID: PMC3769975          DOI: 10.1002/cmdc.201200453

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  12 in total

Review 1.  Endocytosis of influenza viruses.

Authors:  Melike Lakadamyali; Michael J Rust; Xiaowei Zhuang
Journal:  Microbes Infect       Date:  2004-08       Impact factor: 2.700

2.  The significance of p53 and retinoblastoma pathways in canine hemangiosarcoma.

Authors:  Kayoko Yonemaru; Hiroki Sakai; Mami Murakami; Atsushi Kodama; Takashi Mori; Tokuma Yanai; Kohji Maruo; Toshiaki Masegi
Journal:  J Vet Med Sci       Date:  2007-03       Impact factor: 1.267

3.  Evidence that the amantadine-induced, M2-mediated conversion of influenza A virus hemagglutinin to the low pH conformation occurs in an acidic trans Golgi compartment.

Authors:  F Ciampor; P M Bayley; M V Nermut; E M Hirst; R J Sugrue; A J Hay
Journal:  Virology       Date:  1992-05       Impact factor: 3.616

4.  BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.

Authors:  Supriya Gaitonde; Surya K De; Marianna Tcherpakov; Antimone Dewing; Hongbin Yuan; Megan Riel-Mehan; Stan Krajewski; Gavin Robertson; Maurizio Pellecchia; Ze'ev Ronai
Journal:  Pigment Cell Melanoma Res       Date:  2009-01-17       Impact factor: 4.693

5.  CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.

Authors:  Makoto Yamashita; Takanori Tomozawa; Masayo Kakuta; Akane Tokumitsu; Hatsumi Nasu; Shuku Kubo
Journal:  Antimicrob Agents Chemother       Date:  2008-10-27       Impact factor: 5.191

6.  Human host factors required for influenza virus replication.

Authors:  Renate König; Silke Stertz; Yingyao Zhou; Atsushi Inoue; H-Heinrich Hoffmann; Suchita Bhattacharyya; Judith G Alamares; Donna M Tscherne; Mila B Ortigoza; Yuhong Liang; Qinshan Gao; Shane E Andrews; Sourav Bandyopadhyay; Paul De Jesus; Buu P Tu; Lars Pache; Crystal Shih; Anthony Orth; Ghislain Bonamy; Loren Miraglia; Trey Ideker; Adolfo García-Sastre; John A T Young; Peter Palese; Megan L Shaw; Sumit K Chanda
Journal:  Nature       Date:  2010-02-11       Impact factor: 49.962

7.  Structure and mechanism of the M2 proton channel of influenza A virus.

Authors:  Jason R Schnell; James J Chou
Journal:  Nature       Date:  2008-01-31       Impact factor: 49.962

Review 8.  Emerging antiviral targets for influenza A virus.

Authors:  Robert M Krug; James M Aramini
Journal:  Trends Pharmacol Sci       Date:  2009-05-08       Impact factor: 14.819

9.  Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

Authors:  J McKimm-Breschkin; T Trivedi; A Hampson; A Hay; A Klimov; M Tashiro; F Hayden; M Zambon
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

10.  Matrix metalloprotease 9 mediates neutrophil migration into the airways in response to influenza virus-induced toll-like receptor signaling.

Authors:  Linda M Bradley; Mia F Douglass; Dhrubamitra Chatterjee; Shizuo Akira; Bas J G Baaten
Journal:  PLoS Pathog       Date:  2012-04-05       Impact factor: 6.823

View more
  6 in total

1.  Targeting Influenza A Virus RNA Promoter.

Authors:  Angel Bottini; Surya K De; Bainan Wu; Changyan Tang; Gabriele Varani; Maurizio Pellecchia
Journal:  Chem Biol Drug Des       Date:  2015-03-13       Impact factor: 2.817

Review 2.  Development and applications of single-cycle infectious influenza A virus (sciIAV).

Authors:  Aitor Nogales; Steven F Baker; William Domm; Luis Martínez-Sobrido
Journal:  Virus Res       Date:  2015-07-26       Impact factor: 3.303

Review 3.  New-generation screening assays for the detection of anti-influenza compounds targeting viral and host functions.

Authors:  Grant Beyleveld; Kris M White; Juan Ayllon; Megan L Shaw
Journal:  Antiviral Res       Date:  2013-08-06       Impact factor: 5.970

Review 4.  Novel Approaches for The Development of Live Attenuated Influenza Vaccines.

Authors:  Pilar Blanco-Lobo; Aitor Nogales; Laura Rodríguez; Luis Martínez-Sobrido
Journal:  Viruses       Date:  2019-02-22       Impact factor: 5.048

5.  Identification of Quinolinones as Antivirals against Venezuelan Equine Encephalitis Virus.

Authors:  Nicole N Haese; Nicholas A May; Sharon Taft-Benz; Omar Moukha-Chafiq; Nikhil Madadi; Sixue Zhang; Shuklendu D Karyakarte; Kevin J Rodzinak; Theresa H Nguyen; Michael Denton; Aaron D Streblow; Nichole A Towers; Lynn Rasmussen; Robert J Bostwick; Joseph A Maddry; Subramaniam Ananthan; Corinne E Augelli-Szafran; Mark J Suto; Wes Sanders; Nathaniel Moorman; Victor DeFilippis; Mark T Heise; Ashish K Pathak; Daniel N Streblow; Thomas E Morrison
Journal:  Antimicrob Agents Chemother       Date:  2021-08-17       Impact factor: 5.191

6.  miR-29a is a negative regulator of influenza virus infection through targeting of the frizzled 5 receptor.

Authors:  Xiaoyun Yang; Yurong Liang; Gayan Bamunuarachchi; Yanzhao Xu; Kishore Vaddadi; Samuel Pushparaj; Dao Xu; Zhengyu Zhu; Rachel Blaha; Chaoqun Huang; Lin Liu
Journal:  Arch Virol       Date:  2020-11-18       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.